Liver metastases of intrahepatic cholangiocarcinoma: implications for a potential new staging system
La Casta, A.
Ir Macias, R.
Banales, J. M.
Valle, J. W.
AffiliationMedical Oncology / Institute of Cancer Sciences, The Christie NHS Foundation Trust / University of Manchester, Manchester, United Kingdom.
MetadataShow full item record
AbstractBackground: Intrahepatic cholangiocarcinoma (iCCA) with liver metastases (LM) are perceived to have a poor prognosis but the American Joint Committee on Cancer (AJCC) classifies them as early stage in the absence of lymph nodes or extrahepatic spread. Methods: Patients with iCCA from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) and Surveillance, Epidemiology, and End Results (SEER) registries with survival/staging (AJCCv.7) data were eligible. Modified staging was used (mAJCCv.7): Group-A: stages-I-III (excluding T2bN0); Group-B: stage-IVa (excluding T2bN1M0); Group-C: LM (T2bN0/1) and Group-D: stage-IVb (extra-hepatic metastases). Survival analysis (Kaplan Meier and Cox Regression) was performed in an ENS-CCA training cohort (TC) and findings internally [ENS-CCA (iVC)] and externally [SEER] validated. The aim was to assess if LM (Group-C) had a shorter survival compared to other early stages (Group-A). A modified version of AJCCv.8 (mAJCCv.8) is proposed. Results: Total of 574 and 4,171 patients from the ENS-CCA and SEER registries were included. Following the new classification, 19.86% and 17.31% of patients from the ENS-CCA and SEER registries were reclassified into the Group-C, respectively. In the ENS-CCA TC, multivariable Cox Regression was adjusted for obesity (p-value 0.026) and performance status (p-value <0.001); patients in Group-C (HR 2.53 (95%CI 1.18-5.42); p-value 0.017) had a higher risk of death (vs Group-A). Findings were validated in the ENS-CCA iVC (HR 2.93 (95%CI 2.04-4.19); p-value <0.001) and in the SEER registry (HR of 1.88 (95%CI 1.68-2.09); p-value <0.001). Conclusions: iCCA LM have a worse outcome than other early stages. As AJCCv.8 does not take this into consideration, a modification of AJCC v.8 (mAJCCv.8) including "liver metastases: multiple liver lesions, with or without vascular invasion" as a novel "M1a stage" is suggested.
CitationLamarca A, Santos-Laso A, Utpatel K, La Casta A, Stock S, Forner A, et al. Liver metastases of intrahepatic cholangiocarcinoma: implications for a potential new staging system. Hepatology. 2020.
- Reply to "Does multiple intrahepatic cholangiocarcinoma worsen prognosis as "M1" stage?"; multiple primaries vs liver metastases.
- Authors: Lamarca A, Santos-Laso A, Utpatel K, La Casta A, Stock S, Forner A, Adeva J, Folseraas T, Fabris L, Macias RI, Krawczyk M, Krawczyk M, Cardinale V, Braconi C, Alvaro D, Evert M, Banales JM, Valle JW
- Issue date: 2021 Feb 7
- The impact of liver resection on survival for locally advanced intrahepatic cholangiocarcinoma tumors: A propensity score analysis.
- Authors: Moustafa M, Fasolo E, Bassi D, D'amico FE, Gringeri E, Pawlik TM, Cillo U
- Issue date: 2020 Apr
- Effect of liver fibrosis on survival in patients with intrahepatic cholangiocarcinoma: a SEER population-based study.
- Authors: Levy NA, Kern G, Shepshelovich D, Shibolet O, Hershkoviz R, Isakov O
- Issue date: 2020 Nov 24
- Evaluation of the 8th edition American Joint Commission on Cancer (AJCC) staging system for patients with intrahepatic cholangiocarcinoma: A surveillance, epidemiology, and end results (SEER) analysis.
- Authors: Kim Y, Moris DP, Zhang XF, Bagante F, Spolverato G, Schmidt C, Dilhoff M, Pawlik TM
- Issue date: 2017 Nov